Table 2 Sub-group analysis of the odds ratio of relapse risk between subjects with positive and negative MRD-tests.
From: Measurable residual disease (MRD)-testing in haematological and solid cancers
Sub-group | Odds ratio (95-percent CI)a |
|---|---|
Haematological cancers | |
 All (N = 66) | 3.5 (2.3–5.4) |
 Publication year | |
  Before 31 Dec 2018 (N = 33) | 2.3 (1.0–5.4) |
  After 1 Jan 2019 (N = 33) | 4.5 (2.4–8.3) |
 Cancer type | |
  ALL (N = 23) | 2.5 (1.3–4.5) |
  AML (N = 38) | 4.7 (2.6–8.6) |
 Patient age | |
  Adults (N = 39) | 4.4 (2.5–7.6) |
  Children (N = 11) | 1.7 (0.3–9.8) |
 MRD-test time | |
  During or after induction (N = 33) | 1.6 (1.0–2.6) |
  During or after consolidation (N = 9) | 12.8 (5.8–28.6) |
  Before transplant (N = 24) | 6.3 (3.7–10.6) |
  After transplant (N = 9) | 21.0 (6.8–65.3) |
 MRD-test assay | |
  MPFC (N = 31) | 4.4 (2.4–8.1) |
  PCR (N = 24) | 2.2 (0.5–9.4) |
  NGS (N = 8) | 4.9 (1.1–22.1) |
Solid cancers (N = 13) | 9.1 (3.3–24.9) |
